Enanta Pharmaceuticals (ENTA)
(Delayed Data from NSDQ)
$15.17 USD
+1.26 (9.06%)
Updated May 3, 2024 04:00 PM ET
After-Market: $15.18 +0.01 (0.07%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Enanta Pharmaceuticals, Inc. [ENTA]
Reports for Purchase
Showing records 81 - 100 ( 163 total )
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Meet Our COVID-19 Drug Developers Call Series
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
We are sending out a reminder about our 33rd Annual Conference
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Yas'' Weekly Recap of Our Key Notes and 19 Doc Calls Upcoming in 1H20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Do Not Forget to Dial-in to Our NASH Call Today with Dr. Arun Sanyal at 1PM
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Our NASH Expert Call with Dr. Arun Sanyal Moved to Friday, Feb. 21, at 1PM ET
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Do Not Forget to Dial-in to Our Call Today with Dr. Arun Sanyal at 12pm
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Join our Part 2 NASH Call on Feb. 18 with Dr. Arun Sanyal
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Do Not Miss Our NASH Fibrosis Call with Dr. Scott Friedman at 12pm ET
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Dial In to Part 1 of Our Three-Part NASH Call Series Tomorrow at 12PM
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Yas'' Weekly Recap of Our Key Notes and 11 Doc Calls Upcoming in 1H20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Revisit NASH in 2020: Join Our Three-Part Call Series
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Our JPM Takeaways Set the Tone for a Productive 2020
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare -Join Our 1Q20 Doc Call Series in PWS, NASH, Omega-3s and Contraception
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
NASH Weekly: 2020 Is Packed With Clinical Data Readouts in NASH
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y